Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients.
about
Trypanosoma-Cruzi Cross-Reactive Antibodies Longitudinal Follow-Up: A Prospective Observational Study in Hematopoietic Stem Cell Transplantation.Peptide vaccines for hematological malignancies: a missed promise?Vaccination strategies to improve outcome of hematopoietic stem cell transplant in leukemia patients: early evidence and future prospects.Strategies for improving the efficacy of donor lymphocyte infusion following stem cell transplantation.Presensitization to HY antigens in female donors prior to transplant is not associated with male recipient post-transplant HY antibody development nor with clinical outcomes.
P2860
Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Neoantigen and tumor antigen-s ...... lantation in myeloma patients.
@ast
Neoantigen and tumor antigen-s ...... lantation in myeloma patients.
@en
type
label
Neoantigen and tumor antigen-s ...... lantation in myeloma patients.
@ast
Neoantigen and tumor antigen-s ...... lantation in myeloma patients.
@en
prefLabel
Neoantigen and tumor antigen-s ...... lantation in myeloma patients.
@ast
Neoantigen and tumor antigen-s ...... lantation in myeloma patients.
@en
P2093
P2860
P356
P1476
Neoantigen and tumor antigen-s ...... lantation in myeloma patients.
@en
P2093
D H Fowler
D Nattamai
L Radvanyi
M Foglietta
M H Qazilbash
M R Bishop
P2860
P2888
P304
P356
10.1038/BMT.2012.132
P407
P577
2012-07-09T00:00:00Z